Results 81 to 90 of about 5,926 (192)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.

, 2016
We recently discovered mutation signatures reminiscent of BRCA deficiency in the vast majority of a set of primary osteosarcomas (OS). In the current study, we therefore investigated the sensitivity of a panel of OS cell lines to the poly(ADP)-ribose ...
Nathrath, M., Kovac, M., Baumhoer, D., Engert, F., Fulda, S.   +4 more
core   +2 more sources

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer

, 2023
Background: Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or metastatic ...
Mahtani, Reshma
core  

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

Frontiers in Oncology, 2019
The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma.
Paige Baldwin, Rostislav Likhotvorik, Nabeela Baig, Jodie Cropper, Ruth Carlson, Raushan Kurmasheva, Raushan Kurmasheva, Srinivas Sridhar, Srinivas Sridhar, Srinivas Sridhar   +9 more
doaj   +1 more source

NAD+‒circadian rhythm coupling in dementia

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang, Jiyeon Lee, Jun‐ping Pan, Rune Enger, Harald Hrubos‐Strøm, Erik S. Musiek, Evandro Fei Fang, Weidong Le   +7 more
wiley   +1 more source

Abstract B30: Talazoparib efficacy is enhanced by noncytotoxic doses of temozolomide-mediated DNA damage in prostate cancer cell lines

, 2017
Purpose: To investigate the effects of talazoparib alone and in combination with temozolomide (TMZ) on prostate cancer cells Introduction: Talazoparib is a potent, orally bioavailable, small molecule inhibitor of PARP (poly-ADP ribose ...
Olivia Farías, Andrew A. Protter, Jeffrey N. Lindquist, Mohd Raja, Vernon T. Phan, Eduardo Riquelme, Kakoli Mukherjee, Roopa Rai, Hirdesh Uppal, Ashu Gupta   +9 more
core   +1 more source

Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparib

, 2023
Abstract Cancers often have reduced allelic diversity because of loss of heterozygosity (LOH). Therefore, tumors arising in patients heterozygous for a functional and a loss-of-functon(LoF) allele may lose the functional allele, rendering them sensitive to allele-specific therapies.
Tobias Sjöblom, Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Al Azhar, Ioanna Tsiara, Pauline Seeburger, Shahed Al Nassralla, Viktor Ljungström, Richard Svensson, Ivaylo Stoimenov, Per Artursson, Markus Heim, Daniel Globisch   +17 more
openaire   +2 more sources

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Drugs in R&D, 2020
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis   +8 more
doaj   +1 more source

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

, 2019
Malignant hematopoietic cells of myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemias (CMML) and acute myeloid leukemias (AML) may be vulnerable to inhibition of poly(ADP ribose) polymerase 1/2 (PARP1/2) and apurinic/apyrimidinic endonuclease
Wolfgang Seifarth, Johanna Flach, Helga Kleiner, Christel Weiss, Daniel Nowak, Wolf-Karsten Hofmann, Nicole Naumann, Henning D. Popp, Susanne Brendel, Vanessa Kohl, Alice Fabarius   +10 more
core   +1 more source

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

, 2023
Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.
Jonathan Goldman (15047043), Diego Martinez (15047055), Dennis J. Slamon (15047067), Zev A. Wainberg (15047031), Megan M. Price (15047052), Bartosz Chmielowski (15036666), Kelly E. McCann (15047037), Gottfried E. Konecny (15047034), John A. Glaspy (15047064), Arun S. Singh (15036660), J. Randolph Hecht (15047040), Neil O'Brien (15047046), Richard S. Finn (10431048), Erika Von Euw (15047049), Meghan Brennan (15047061), Lisa Yonemoto (15047058)   +15 more
core   +1 more source

Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers

Advanced Science
Synthetic lethality in homologous recombination (HR)‐deficient cancers caused by Poly (ADP‐ribose) polymerase inhibitors (PARPi) has been classically attributed to its role in DNA repair.
Ganesh Pai Bellare, Kshama Kundu, Papiya Dey, Krupa Thankam Philip, Nitish Chauhan, Muskan Sharma, Sankarsingh Kesharsingh Rajput, Birija Sankar Patro   +7 more
doaj   +1 more source